Zydus Lifesciences Ltd Financials
Company Logo

Zydus Lifesciences Ltd Financial Statement

Zydus Lifesciences Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Mar 2025
Revenue6005.00
Operating Expense2046.90
Net Profit2813.70
Net Profit Margin46.86
Earning Per Share27.96
EBIDTA3923.60
Effective Tax Rate20.88

Zydus Lifesciences Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue Annual10,818.70
Operating Expenses Annual6,760
Operating Profit Annual5,134.90
Interest Annual390.70
Depreciation504.40
Net Profit Annual3,441.50
Tax Annual798.30

Zydus Lifesciences Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the Beginning240.40
Cash Flow from Operations1,999.10
Cash Flow from Investing-1,830.60
Cash Flow from Financing-300.80
Cash Flow at the End108.10

Zydus Lifesciences Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)47.46
PBIT Margin (%)42.80
PBT Margin (%)42.69
Net PROFIT Margin (%)31.81
Return On Networth / Equity (%)23.45
Return On Networth /Employed (%)22.73
Return On Assets (%)16.86
Total Debt / Equity (X)0.37
Asset Turnover Ratio (%)0.53

Zydus Lifesciences Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual4,376.60
Total Current Assets Annual7,911.30
Non Current Assets Annual16,149
Total Shareholders Funds Annual15,716.50
Total Assets Annual24,084.80

Zydus Lifesciences Ltd Earning Calls

EPS (INR)

Expected

11.64

Reported

11.64

Surprise

0.00%

Dec 2024

EPS beaten by 0.00%

Sep 2024

EPS beaten by 0.00%

Jun 2024

EPS beaten by 0.00%

FAQS on Zydus Lifesciences Ltd Financials

As of Jun 2, 2025, Zydus Lifesciences Ltd has a market capitalization of 89,122.14 Cr. Value Research classifies it as a Large-Cap company.

Yes, Zydus Lifesciences Ltd is with a debt-to-equity ratio of 0.39.

In FY 2024 , Zydus Lifesciences Ltd recorded a total revenue of approximately 14,590.10 Cr marking a significant milestone in the company's financial performance.

Zydus Lifesciences Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.3% and 0.3% annually, respectively..

Zydus Lifesciences Ltd's current PE ratio is 15.43.

Zydus Lifesciences Ltd's ROCE averaged 20.5% from the FY ending March 2023 to 2025, with a median of 21.1%. It peaked at 26.8% in March 2025, reflecting strong capital efficiency over the period..

Zydus Lifesciences Ltd's latest EBIT is Rs. 7,908.60 Cr, surpassing the average EBIT of Rs. 4,949.83 Cr over the 5 years..

Join the Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions